Treatment rates for dangerously high cholesterol remains low
DALLAS, March 26, 2018 — Less than 40 percent of people with severe elevations in cholesterol are being prescribed appropriate drug treatment, according to a nationally representative study reported in the American Heart Association's journal Circulation.
Data from the 1999-2014 National Health and Nutrition Examination Survey was used to estimate prevalence rates of self-reported screening, awareness and statin therapy among U.S. adults age 20 and older with severely elevated LDL or "bad cholesterol" levels of 190 mg/dL or higher. In addition, they considered a subgroup of patients with familial hypercholesterolemia, a genetic disorder that causes extreme elevations in cholesterol leading to an increased risk of early cardiovascular disease.
The frequency of cholesterol screening and awareness were high (at more than 80 percent) among adults with definite/probable familial hypercholesterolemia and severely elevated cholesterol; however, use of cholesterol-lowering statins was low (38 percent). Of those, only 30 percent of patients with severely elevated cholesterol had been prescribed a high intensity statin.
The discrepancy between cholesterol screening and medical treatment was most pronounced in younger patients, uninsured patients and patients without a regular source of healthcare – such as a doctor's office or an outpatient clinic.
"Young adults may be less likely to think that they are at risk of cardiovascular disease, and clinicians may be less likely to initiate statin therapy in this population," wrote lead author Emily Bucholz, M.D., Ph.D., MPH, Department of Medicine at Boston Children's Hospital in Massachusetts. "It is possible that lifestyle modifications continue to be prescribed as an initial treatment prior to initiating statin therapy."
However, both the original 2002 National Cholesterol Education Program's Adult Treatment Panel III (ATP-III guidelines) and the current American College of Cardiology and American Heart Association cholesterol guidelines recommend initiation of statin therapy in patients with LDL cholesterol at or above 190 mg/dL.
"Markedly elevated levels of 'bad' cholesterol put you at increased risk of developing heart disease and developing it earlier in life," said Circulation Editor-in-Chief, Joseph A. Hill. "If your 'bad' cholesterol is over 190 you should work with your physician regarding optimal drug treatment, in addition to lifestyle changes and management of other risk factors."
Study authors said additional studies are needed to better understand how to close these gaps of screening and treatment.
The authors indicate no conflicts of interest. Funding information is listed on the manuscript.
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at http://www.heart.org/corporatefunding.
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation's oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.
Related Journal Article